Vineet Laboratories Rights Issue Fund Utilization Update

Rs 1,353.68 Lakhs Utilized, Rs 1,642.50 Lakhs Unutilized as of June 30, 2026.

Reader Takeaway: Bank loans repaid, but project delays may impact deployment pace.

What just happened

CRISIL Ratings, acting as the Monitoring Agency, provided an update on Vineet Laboratories Limited's utilization of funds from its January 2026 Rights Issue. As of June 30, 2026, the company has utilized Rs 1,353.68 lakhs out of the Rs 2,996.18 lakhs raised.

Why this matters

This update is crucial for investors as it details how the capital raised is being deployed. While bank loans have been fully repaid, significant amounts remain unutilized for business expansion and effluent treatment plant projects, with revised timelines indicating delays into FY2027.

The backstory

Vineet Laboratories raised Rs 2,996.18 lakhs through a Rights Issue in January 2026. The funds were earmarked for repayment of bank loans, setting up an effluent treatment plant, business expansion, and general corporate purposes.

What changes now

The company plans to finalize implementation plans and utilize the remaining Rs 1,642.50 lakhs in subsequent periods, as approved by the board. The previously reported inadvertent diversion of Rs 25.91 lakhs has been rectified by transferring the amount back.

Risks to watch

Project implementation delays for the effluent treatment plant and business expansion could impact the company's growth plans. The significant unutilized amount also warrants investor attention regarding the timeline for deployment.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Total Rights Issue Proceeds: Rs 2,996.18 lakhs (January 2026)
• Amount Utilized (as of June 30, 2026): Rs 1,353.68 lakhs
• Amount Unutilized (as of June 30, 2026): Rs 1,642.50 lakhs
• Repayment of Bank Loans: Fully utilized (Rs 284.00 lakhs)
• Effluent Treatment Plant: Rs 270.00 lakhs allocated, Rs 33.75 lakhs utilized.
• Expansion of Business: Rs 1,696.35 lakhs allocated, Rs 293.65 lakhs utilized.
• General Corporate Purposes: Rs 670.83 lakhs allocated, Rs 670.66 lakhs utilized.
• Issue Expenses: Rs 75.00 lakhs allocated, Rs 71.62 lakhs utilized.
• Inadvertent Fund Diversion: Rs 25.91 lakhs (rectified August 5, 2026).

What to track next

Investors should closely monitor future updates from CRISIL Ratings regarding the actual utilization of the remaining funds and the progress of project implementation against the revised timelines.